Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From Amolyt Pharma

Q1 2024 Posts Big M&A Total Led By Novo Holdings’ Catalent Takeout

The $16.5bn deal, intended to increase Novo Nordisk’s production of semaglutide-containing products, led a $36bn-plus quarter for M&A transactions, according to Evaluate.

Evaluate Data M & A

Andera Reflects On Revitalized Biotech Scene

After AstraZeneca’s acquisition of Amolyt made the Paris-based investment group a tidy profit, Andera spoke to Scrip about the rejuvenated investment market in Europe.

M & A Business Strategies

AstraZeneca Spends $800m On Amolyt And Awaits A Readout

The Phase III trial of hypoparathyroidism asset eneboparatide will have to hit if AstraZeneca is going to carve out market share from Ascendis.

Deals Commercial

Hopes For A ‘New Era’ In UK Biotech Financing With Pension-Backed Fund

Backed by the UK government and the Phoenix Group, the initial £200m fund is aimed at convincing pension funds to invest in the higher-risk, higher-reward life sciences sector.

Commercial Financing
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Alizé Pharma III
    • Alizé Pharma 3